- |||||||||| Torisel (temsirolimus) / Pfizer
Trial primary completion date: Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 22, 2017 P4, N=90, Active, not recruiting, Our collective results demonstrate that Reolysin possesses CXCL10-driven anti-angiogenic activity in sarcoma models, which can be harnessed to enhance the anticancer activity of temsirolimus and other agents that target the tumor vasculature. Trial primary completion date: May 2016 --> Nov 2015
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination, Metastases: Second Line Sorafenib After Pazopanib in Patients With RCC (clinicaltrials.gov) - Nov 22, 2017 P2, N=16, Terminated, Trial primary completion date: May 2016 --> Nov 2015 N=44 --> 16 | Recruiting --> Terminated; availability of new and more promising therapeutic agents than expected in the experimentation in question
- |||||||||| Trial initiation date: NCT Neuro Master Match - N (clinicaltrials.gov) - Nov 1, 2017
P1/2, N=350, Not yet recruiting, Trial primary completion date: Dec 2017 --> Apr 2018 Initiation date: Jul 2017 --> Jan 2018
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (clinicaltrials.gov) - Oct 25, 2017 P1, N=278, Active, not recruiting, Cancer 2017;123:4114-4121. Trial primary completion date: Aug 2018 --> Aug 2019
- |||||||||| everolimus / Generic mfg., Torisel (temsirolimus) / Pfizer
Biomarker, Review, Journal: Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. (Pubmed Central) - Sep 21, 2017 Challenges to the therapeutic effectiveness of some PI3K inhibitors include the absence of reliable and effective biomarkers, their limited efficacy as single agents, insufficient development of rational therapeutic combinations, the use of schedules with a variety of off-target effects, and suboptimal therapeutic exposures. Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice.
- |||||||||| perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Journal: A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. (Pubmed Central) - Sep 16, 2017 Therefore, with regard to PI3K inhibitors currently in late-stage clinical trials, the identification of appropriate biomarkers of efficacy and the development of optimal combination regimens and dosing schedules are likely to be important for graduation into clinical practice. The combination of these AKT and mTOR inhibitors was safe and feasible in patients with recurrent/refractory pediatric solid tumors.
- |||||||||| Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
Enrollment closed, Enrollment change, Trial primary completion date: Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Sep 12, 2017 P2, N=69, Active, not recruiting, Further evaluation of biomarkers in a larger cohort of patients might identify those most likely to respond to this chemoimmunotherapeutic regimen. Recruiting --> Active, not recruiting | N=90 --> 69 | Trial primary completion date: Oct 2018 --> Oct 2019
- |||||||||| Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: BERT: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 11, 2017 P1/2, N=39, Completed, Recruiting --> Active, not recruiting | N=90 --> 69 | Trial primary completion date: Oct 2018 --> Oct 2019 Active, not recruiting --> Completed | N=72 --> 39 | Trial primary completion date: Mar 2016 --> Sep 2017
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Second Line Sorafenib After Pazopanib in Patients With RCC (clinicaltrials.gov) - Aug 28, 2017 P2, N=44, Recruiting, Active, not recruiting --> Completed | N=72 --> 39 | Trial primary completion date: Mar 2016 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2016 | Trial primary completion date: Apr 2016 --> Dec 2017
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer (clinicaltrials.gov) - Aug 3, 2017
P2, N=4, Terminated, Initiation date: Mar 2014 --> Aug 2014 N=100 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Loss of laboratory performing molecular analysis
- |||||||||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Combination therapy, Metastases: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (clinicaltrials.gov) - Jul 26, 2017 P1, N=140, Active, not recruiting, Inhibition of PI3K signalling was detected in patients treated at all dose levels of temsirolimus, but inhibition at an early time point did not appear to correlate with clinical responses at the end of re-induction therapy. N=211 --> 140
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 11, 2017 P2, N=252, Completed, N=104 --> 62 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed, Trial primary completion date, Metastases: Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (clinicaltrials.gov) - Jun 27, 2017 P1/2, N=49, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Metastases: Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 16, 2017 P1, N=25, Completed, Trial primary completion date: Sep 2017 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2012 --> Sep 2012
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Trial primary completion date: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - May 31, 2017 P1, N=200, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Apr 2012 --> Sep 2012 Completed --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Aug 2018
- |||||||||| Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Trial primary completion date, Epigenetic controller, Metastases: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) - May 22, 2017 P1, N=249, Active, not recruiting, Response rate and median PFS suggest clinical activity for this combination strategy in previously treated ccRCC. Trial primary completion date: Mar 2018 --> Mar 2019
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Journal: The clinical management of inoperable endometrial carcinoma. (Pubmed Central) - May 5, 2017 Given the paucity of inoperable disease, randomized clinical data is lacking in this specific patient population. Management decisions regarding radiation therapy or systemic therapy are largely guided by the existing data in the setting of recurrence or second-line treatment, adjuvant therapy following optimal debulking, or in patients who are considered inoperable due to medical comorbidities rather than the extent of their disease.
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Apr 26, 2017 P1/2, N=48, Active, not recruiting, Management decisions regarding radiation therapy or systemic therapy are largely guided by the existing data in the setting of recurrence or second-line treatment, adjuvant therapy following optimal debulking, or in patients who are considered inoperable due to medical comorbidities rather than the extent of their disease. Trial primary completion date: Nov 2017 --> Nov 2018
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 12, 2017 P2, N=73, Completed, A randomized trial should be performed to test DAT and DAE for metaplastic TNBC, as well as nonmetaplastic, mesenchymal TNBC, especially when PI3K pathway aberrations are identified. Active, not recruiting --> Completed
|